Effect of simvastatin on monocyte chemoattractant protein-1 expression in endometriosis patients: a randomized controlled trial
Background: Simvastatin is a promising new drug for the treatment of endometriosis. It is a cholesterol-lowering drug that acts by inhibiting HMG-CoA reductase, resulting in a decrease in mevalonate, a precursor of cholesterol and monocyte chemoattractant protein-1 (MCP-1). This study investigated...
Saved in:
Main Authors: | , , , , |
---|---|
Other Authors: | |
Format: | Article |
Language: | English |
Published: |
2017
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/3229 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
Language: | English |
Summary: | Background: Simvastatin is a promising new drug for the treatment of endometriosis. It is a cholesterol-lowering
drug that acts by inhibiting HMG-CoA reductase, resulting in a decrease in mevalonate, a precursor of cholesterol
and monocyte chemoattractant protein-1 (MCP-1). This study investigated the effect of pre-operative oral simvastatin
administration on MCP-1 gene expression and serum MCP-1 protein levels in patients with endometriosis.
Methods: A prospective, randomized, controlled study was conducted at the Reproductive Endocrinology Unit of the
Department of Obstetrics and Gynecology at the Faculty of Medicine Ramathibodi Hospital. Forty women (mean age:
18–45 years) scheduled for laparoscopic surgery who had been diagnosed with endometriosis were recruited and
randomly assigned to either a treatment group (20 mg/d of orally administered simvastatin for 2 weeks before surgery)
or an untreated control group. Serum was collected before and after treatment and protein levels of MCP-1 were
determined. MCP-1 and CD68 transcript levels were also quantified using real-time PCR on endometriotic cyst tissues.
Results: MCP-1 gene expression on endometriotic cyst was not significantly different between the simvastatin-treated
and untreated groups (P = 0.99). CD68 expression was higher in the treatment group compared to the control group,
but this was not statistically significant (P = 0.055). Serum MCP-1 levels following simvastatin treatment were higher
than in samples obtained before treatment (297.89 ± 70.77 and 255.51 ± 63.79 pg/ml, respectively) (P = 0.01).
Conclusions: Treatment with 20 mg/d of simvastatin for 2 weeks did not reduce the expression of either the
chemokine MCP-1 gene or macrophage-specific genes. Cumulatively, this suggests that simvastatin is not ideal for
treating endometriosis because a higher dose of simvastatin (40–100 mg/d) would be needed to achieve the
target outcome, which would significantly increase the risk of myopathy in patients.
Trial registration: Thai Clinical Trials Registry TCTR20130627003 Registered: June 27, 2013. |
---|